home / stock / kura / kura quote
Last: | $19.40 |
---|---|
Change Percent: | 2.11% |
Open: | $19.2 |
Close: | $19 |
High: | $19.5 |
Low: | $18.95 |
Volume: | 158,712 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$19.4 | $19.2 | $19 | $19.5 | $18.95 | 158,712 | 04-26-2024 |
$19 | $18.26 | $19 | $19.22 | $17.96 | 830,677 | 04-25-2024 |
$18.75 | $18.75 | $18.75 | $18.92 | $18.41 | 665,435 | 04-24-2024 |
$18.73 | $18.12 | $18.73 | $19.27 | $18.12 | 1,038,202 | 04-23-2024 |
$18.19 | $18.33 | $18.19 | $19.18 | $17.92 | 2,099,668 | 04-22-2024 |
$17.53 | $17.61 | $17.53 | $17.9 | $16.79 | 1,329,668 | 04-19-2024 |
$17.68 | $17.86 | $17.68 | $18.05 | $17.52 | 1,653,399 | 04-18-2024 |
$17.99 | $18.8 | $17.99 | $18.89 | $17.89 | 660,270 | 04-17-2024 |
$18.59 | $18.81 | $18.59 | $18.945 | $18.41 | 821,071 | 04-16-2024 |
$19.01 | $19.57 | $19.01 | $19.7 | $18.59 | 751,803 | 04-15-2024 |
$19.48 | $20.3 | $19.48 | $20.3 | $19 | 637,108 | 04-12-2024 |
$20.4 | $20.04 | $20.4 | $20.62 | $20.04 | 764,312 | 04-11-2024 |
$19.9 | $20.07 | $19.9 | $20.24 | $19.7 | 869,070 | 04-10-2024 |
$20.68 | $20.44 | $20.68 | $20.81 | $20 | 404,859 | 04-09-2024 |
$20.42 | $20.65 | $20.42 | $20.76 | $20.12 | 304,440 | 04-08-2024 |
$20.36 | $20.09 | $20.36 | $20.81 | $19.58 | 599,650 | 04-05-2024 |
$20.36 | $20.58 | $20.36 | $21.38 | $20.2 | 918,005 | 04-04-2024 |
$20.34 | $20.29 | $20.34 | $20.826 | $20.23 | 553,569 | 04-03-2024 |
$20.52 | $21.3 | $20.52 | $21.3 | $20.27 | 752,861 | 04-02-2024 |
$21.82 | $21.19 | $21.82 | $21.89 | $20.975 | 705,380 | 04-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizi...
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2024 financial results after the cl...
– Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – SAN DIEGO, April 22, 2024 (GLOB...